Correction: Comparative analysis of glucagon-like peptide-1 receptor agonists, metformin, and inositol in improving anthropometric and metabolic outcomes in women with polycystic ovary syndrome: a network meta-analysis - Report - MDSpire
Advertisement
Correction: A Network Meta-Analysis Comparing Glucagon-Like Peptide-1 Receptor Agonists, Metformin, and Inositol on Anthropometric and Metabolic Improvements in Women with Polycystic Ovary Syndrome
Correction: A Network Meta-Analysis Comparing GLP-1 Agonists, Metformin, and Inositol
Overview
This correction addresses the misalignment of figure captions in a network meta-analysis comparing glucagon-like peptide-1 receptor agonists, metformin, and inositol for polycystic ovary syndrome (PCOS). The corrected captions now accurately correspond to their respective figures.
Background
Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder that impacts women's health, particularly concerning obesity and insulin resistance. Effective management often requires pharmacological interventions alongside lifestyle modifications.
Data Highlights
No numerical or trial data is presented in the correction notice.
Key Findings
The correction aligns figure captions with their respective images in the analysis.
Figure 3 illustrates the network plot of treatment comparisons.
Figure 4 presents a forest plot for BMI change versus placebo.
Figure 5 shows a forest plot for waist circumference change versus placebo.
Figure 6 depicts a forest plot for HOMA-IR change versus placebo.
Clinical Implications
This correction ensures that practitioners can rely on the visual data presented in the analysis for understanding treatment comparisons in PCOS.
Conclusion
The correction enhances the accuracy of the network meta-analysis.
